Gerd Steiner

This inventor holds 53 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Pyrimidine Compounds (CPC class 5142). Top assignees: Basf Aktiengesellschaft, Abbott Laboratories Corporation, Abbott Gmbh & Co Kg. Active years: 1982-2012.

USPTO Granted Patents = 53 (Patent Applications = 1)

% Patents Active = 83.0

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 3.8

ph-index = 8

Forward Citations = 238(Granted Patents)

Forward Citations (Not Self Cited) = 215(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Kircheim, DE (2009)
Kirchheim, DE (1982 - 2012)

Company Filing History:

46 out of 10,816

Basf Aktiengesellschaft

patents

4 out of 4,186

Abbott Laboratories Corporation

Years Active: 1982-2012

Loading Chart...

Areas of Expertise:

Pyrimidine Compounds

Azabicycloheptane Derivatives

N-Substituted Compounds

Neuroleptics

Cerebral Ischaemia

Serotonin Antagonists

Dicarboximides

Carboxamides

Herbicides

Anti-Anxiety

Nematicides

Thieno Derivatives

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8268815 - Pyrimidine compounds and use thereof (2012-09-18),

2. 7786105 - Pyrimidine compounds and use thereof (2010-08-31),

3. 7494663 - Cyanomethyl trithiocarbonates as nematicides (2009-02-24),

4. 7491729 - 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof (2009-02-17),

5. 6750221 - Use of 5-ht5-ligands in the treatment of neurodegenerative and neuropsychiatric disturbances (2004-06-15),

6. 6458821 - N-substituted azabicycloheptane derivatives, production and use thereof (2002-10-01),

7. 6414157 - 3-Substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use (2002-07-02),

8. 6387912 - Utilization of pyrimidine derivatives for preventing and treating cerebral ischaemia (2002-05-14),

9. 6355647 - 3-substituted 3,4,5,7-tetrahedropyrrolo[3′,4′:4,5]thieno-[2,3-d]pyrimidine derivatives, their preparation and use (2002-03-12),

10. 6346622 - 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-HT1A, 5HT1B and 5-HT1D) (2002-02-12),

11. 6328855 - Method for producing (+)-exo-6-phenyl-3-azabicyclo-[3.2.0]heptanes (2001-12-11),

12. 6300354 - N-substituted azabicycloheptane derivatives, production and use thereof (2001-10-09),

13. 6222034 - 3-substituted pyrido[4′,3′:4,5]thieno[2,3-d]pyrimidine derivatives, their preparation and their use (2001-04-24),

14. 6159981 - 3-substituted pyrido [3',4':4,5] Thieno [2,3-d] pyrimidine derivatives, (2000-12-12),

15. 6159962 - 3-substituted 3,4-dihydro-thieno[2,3-D]pyrimidine derivatives and (2000-12-11),

Title: Gerd Steiner: A Pioneer in Pyrimidine Compounds

Introduction

Gerd Steiner, a prolific inventor based in Kirchheim, Germany, has made significant contributions to the field of medicinal chemistry with a total of 53 patents to his name. His work primarily focuses on the development of pyrimidine compounds, which have broad applications in pharmaceuticals.

Latest Patents

Among his latest innovations are patents related to pyrimidine compounds and their use in treating diseases linked to dopamine D receptor antagonists or agonists. One notable invention involves compounds of formula (I) and their use in creating pharmaceutical agents aimed at addressing various medical conditions. These advancements demonstrate his commitment to improving healthcare through innovative chemical solutions.

Career Highlights

Gerd Steiner's career includes significant roles at prominent companies, such as BASF Aktiengesellschaft and Abbott Laboratories Corporation. His tenure at these organizations has been marked by groundbreaking research and development initiatives, further solidifying his reputation in the industry.

Collaborations

Throughout his career, Gerd has collaborated with notable scientists, including Hans-Juergen Teschendorf and Liliane Unger. These partnerships have fostered a rich exchange of ideas and innovative approaches to the challenges faced in pharmaceutical development.

Conclusion

With a vast portfolio of patents and a collaborative spirit, Gerd Steiner continues to be a key figure in the field of medicinal chemistry. His inventions not only enhance our understanding of pyrimidine compounds but also pave the way for novel treatments that have the potential to change lives. As he advances his work, the impact of his contributions will undoubtedly be felt across the pharmaceutical industry for years to come.